196 related articles for article (PubMed ID: 35960210)
1. Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine.
Wang H; Chan KYY; Cheng CK; Ng MHL; Lee PY; Cheng FWT; Lam GKS; Chow TW; Ha SY; Chiang AKS; Leung WH; Leung AYH; Wang CC; Zhang T; Zhang XB; So CC; Yuen YP; Sun Q; Zhang C; Xu Y; Cheung JTK; Ng WH; Tang PM; Kang W; To KF; Lee WYW; Wong RSM; Poon ENY; Zhao Q; Huang J; Chen C; Yuen PMP; Li CK; Leung AWK; Leung KT
Blood Cancer Discov; 2022 Nov; 3(6):516-535. PubMed ID: 35960210
[TBL] [Abstract][Full Text] [Related]
2. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Malani D; Kumar A; Brück O; Kontro M; Yadav B; Hellesøy M; Kuusanmäki H; Dufva O; Kankainen M; Eldfors S; Potdar S; Saarela J; Turunen L; Parsons A; Västrik I; Kivinen K; Saarela J; Räty R; Lehto M; Wolf M; Gjertsen BT; Mustjoki S; Aittokallio T; Wennerberg K; Heckman CA; Kallioniemi O; Porkka K
Cancer Discov; 2022 Feb; 12(2):388-401. PubMed ID: 34789538
[TBL] [Abstract][Full Text] [Related]
3. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
[TBL] [Abstract][Full Text] [Related]
5. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
Swords RT; Azzam D; Al-Ali H; Lohse I; Volmar CH; Watts JM; Perez A; Rodriguez A; Vargas F; Elias R; Vega F; Zelent A; Brothers SP; Abbasi T; Trent J; Rangwala S; Deutsch Y; Conneally E; Drusbosky L; Cogle CR; Wahlestedt C
Leuk Res; 2018 Jan; 64():34-41. PubMed ID: 29175379
[TBL] [Abstract][Full Text] [Related]
6. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets.
Hoff FW; Hu CW; Qiu Y; Ligeralde A; Yoo SY; Mahmud H; de Bont ESJM; Qutub AA; Horton TM; Kornblau SM
Mol Cancer Res; 2018 Aug; 16(8):1275-1286. PubMed ID: 29669821
[TBL] [Abstract][Full Text] [Related]
7. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.
Stratmann S; Yones SA; Mayrhofer M; Norgren N; Skaftason A; Sun J; Smolinska K; Komorowski J; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Cavelier L; Holmfeldt L
Blood Adv; 2021 Feb; 5(3):900-912. PubMed ID: 33560403
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Burd A; Levine RL; Ruppert AS; Mims AS; Borate U; Stein EM; Patel P; Baer MR; Stock W; Deininger M; Blum W; Schiller G; Olin R; Litzow M; Foran J; Lin TL; Ball B; Boyiadzis M; Traer E; Odenike O; Arellano M; Walker A; Duong VH; Kovacsovics T; Collins R; Shoben AB; Heerema NA; Foster MC; Vergilio JA; Brennan T; Vietz C; Severson E; Miller M; Rosenberg L; Marcus S; Yocum A; Chen T; Stefanos M; Druker B; Byrd JC
Nat Med; 2020 Dec; 26(12):1852-1858. PubMed ID: 33106665
[TBL] [Abstract][Full Text] [Related]
9. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
Lam SS; He AB; Leung AY
Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
[TBL] [Abstract][Full Text] [Related]
11. [Precision medicine for acute myeloid leukemia based on genomic profiling].
Sanada M
Rinsho Ketsueki; 2019; 60(7):847-853. PubMed ID: 31391376
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.
Shiba N; Yoshida K; Hara Y; Yamato G; Shiraishi Y; Matsuo H; Okuno Y; Chiba K; Tanaka H; Kaburagi T; Takeuchi M; Ohki K; Sanada M; Okubo J; Tomizawa D; Taki T; Shimada A; Sotomatsu M; Horibe K; Taga T; Adachi S; Tawa A; Miyano S; Ogawa S; Hayashi Y
Blood Adv; 2019 Oct; 3(20):3157-3169. PubMed ID: 31648321
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine for acute myeloid leukemia.
Lai C; Karp JE; Hourigan CS
Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
[TBL] [Abstract][Full Text] [Related]
14. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
15. An
Lin S; Larrue C; Scheidegger NK; Seong BKA; Dharia NV; Kuljanin M; Wechsler CS; Kugener G; Robichaud AL; Conway AS; Mashaka T; Mouche S; Adane B; Ryan JA; Mancias JD; Younger ST; Piccioni F; Lee LH; Wunderlich M; Letai A; Tamburini J; Stegmaier K
Cancer Discov; 2022 Feb; 12(2):432-449. PubMed ID: 34531254
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia.
Lilljebjörn H; Orsmark-Pietras C; Mitelman F; Hagström-Andersson A; Fioretos T
Semin Cancer Biol; 2022 Sep; 84():40-49. PubMed ID: 34606984
[TBL] [Abstract][Full Text] [Related]
17. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
Collignon A; Hospital MA; Montersino C; Courtier F; Charbonnier A; Saillard C; D'Incan E; Mohty B; Guille A; Adelaïde J; Carbuccia N; Garnier S; Mozziconacci MJ; Zemmour C; Pakradouni J; Restouin A; Castellano R; Chaffanet M; Birnbaum D; Collette Y; Vey N
Blood Cancer J; 2020 Jun; 10(6):64. PubMed ID: 32488055
[TBL] [Abstract][Full Text] [Related]
18. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M
Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916
[TBL] [Abstract][Full Text] [Related]
19. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
Simonetti G; Padella A; do Valle IF; Fontana MC; Fonzi E; Bruno S; Baldazzi C; Guadagnuolo V; Manfrini M; Ferrari A; Paolini S; Papayannidis C; Marconi G; Franchini E; Zuffa E; Laginestra MA; Zanotti F; Astolfi A; Iacobucci I; Bernardi S; Sazzini M; Ficarra E; Hernandez JM; Vandenberghe P; Cools J; Bullinger L; Ottaviani E; Testoni N; Cavo M; Haferlach T; Castellani G; Remondini D; Martinelli G
Cancer; 2019 Mar; 125(5):712-725. PubMed ID: 30480765
[TBL] [Abstract][Full Text] [Related]
20. Personalized therapy for acute myeloid leukemia.
Hourigan CS; Karp JE
Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
